The Hematopathology Section of the Laboratory of Pathology, NCI, offers expert diagnostic services in the field of hematopathology. Dr. Stefania Pittaluga, Staff Clinician, and I handle diagnostic service responsibilities equally, each rotating as the staff on service 50% of the time. However, because of the challenging nature of the material we receive for review, and obligations related to specific clinical protocols and teaching conferences, our clinical obligations extend well beyond the designated on-service time. We provide assistance in the diagnosis and classification of reactive and neoplastic lymphoproliferative disorders, immunodeficiency states, and diverse hematological malignancies. We provide consultative and collaborative services to physicians in the National Cancer Institute, as well as to physicians studying patients with hematolymphoid disorders in other institutes, in particular NIAID, NHLBI, NHGRI, and NIAMSD. We serve as Associate Investigators on more than 35 clinical protocols being conducted in the NCI and other NIH institutes. These protocols frequently mandate specialized testing to illuminate biological markers relevant to the particular study. We receive more than 2000 cases in consultation each year. Because of the demands that the consultation service places on our time, we try to restrict consultations to difficult or challenging cases. Many cases are submitted by other academic institutions, based on diagnostic uncertainty, or because of differences of opinion among several institutions. We regularly refuse to accept consultations that we regard to be of a routine nature, and recommend that such cases be sent to routine reference laboratories. We frequently make novel observations based on this unique clinical practice, and a number of publications have emanated these experiences. Thus, I believe our clinical work enhances, rather than detracts, from our academic productivity.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
National Cancer Institute Division of Basic Sciences
Zip Code
Roswarski, Joseph; Roschewski, Mark; Lucas, Andrea et al. (2018) Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas. Leuk Lymphoma 59:1466-1469
Wu, David; Lim, Megan S; Jaffe, Elaine S (2018) Pathology of Castleman Disease. Hematol Oncol Clin North Am 32:37-52
Egan, Caoimhe; Jaffe, Elaine S (2018) Non-neoplastic histiocytic and dendritic cell disorders in lymph nodes. Semin Diagn Pathol 35:20-33
Fajgenbaum, David C; Uldrick, Thomas S; Bagg, Adam et al. (2017) International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 129:1646-1657
Gru, Alejandro A; Jaffe, Elaine S (2017) The Landscape of Cutaneous Lymphomas in 2016, An Introduction. Semin Diagn Pathol 34:1-2
Gratzinger, Dita; Jaffe, Elaine S; Chadburn, Amy et al. (2017) Primary/Congenital Immunodeficiency: 2015 SH/EAHP Workshop Report-Part 5. Am J Clin Pathol 147:204-216
Jaffe, Elaine S; Barr, Paul M; Smith, Sonali M (2017) Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice. Am Soc Clin Oncol Educ Book 37:535-546
Jaffe, Elaine S (2017) The Microscope as a Tool for Disease Discovery-A Personal Voyage. Annu Rev Pathol 12:1-24
Gratzinger, Dita; de Jong, Daphne; Jaffe, Elaine S et al. (2017) T- and NK-Cell Lymphomas and Systemic Lymphoproliferative Disorders and the Immunodeficiency Setting: 2015 SH/EAHP Workshop Report-Part 4. Am J Clin Pathol 147:188-203
Sharma, Kamal; Janik, John E; O'Mahony, Deirdre et al. (2017) Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma. Clin Cancer Res 23:35-42

Showing the most recent 10 out of 138 publications